and found that EGFR activity did not predict response to the KRASG12C inhibitors. This suggests that RAS–RAF interaction is a more accurate biomarker for treatment response. "This research opens ...

the pathway might be important in mediating EGFR-mutant signals, and therefore the inhibition of Ras or Raf in combination with gefitinib or erlotinib might have some benefit. The MEK inhibitor PD ...

Cdc2 inhibition is able to restore EGF-, Ras- and Raf-1-mediated ERK activation. The data suggest that Cdc2 is able to inhibit EGFR-mediated ERK activation upstream of the MEKs, indicating that ...